Takeda has officially emerged victorious in the battle for Shire. The Japanese drug giant will pay more than $66/share to acquire Shire in a deal valued at $62 billion....more
The US and South Korea have announced a deal to renegotiate their trade pact, with “South agreeing to reduce its steel exports and open its market to American cares” in exchange for an exemption from the White House’s steel...more
Generic drugmaking giant Teva Pharmaceuticals will cut 25% of its workforce (around 14,000 jobs) and shutter manufacturing and R&D facilities in an effort to “simplify its structure and reduce its debt”....more
Following up on news last week that Bill Ackman was finally done with his grand Valeant experiment, the Times gives us a deeper look at what was really going on with the activist investor’s bet and ultimate $4 billion loss....more
Activist investor Carl Icahn has taken a sizeable stake in Bristol-Myers Squibb, a move that reportedly caught execs at the drugmaker unawares and sets the stage for a potential sale....more
Theranos is “retreating” from its blood tests, cutting its workforce by 40 percent, and shuttering facilities—all signs that Elizabeth Holmes’ company may be shifting to developing products to sell to outside labs rather than...more